Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Home2024-01-09T21:17:33+00:00

The Future of
Drug Discovery is Here.

Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. We leverage our proprietary end-to-end platform to enable our biotechnology and pharmaceutical partners to deliver benefits to patients around the world.

Who We Are

Axcelead is your trusted drug discovery and development partner.

We were formed in 2017 as a Takeda spin-out with a singular vision in mind – to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines.

What We Do

Oncology, immunology, neuroscience drug discovery and so much more.

At Axcelead, we are focused on accelerating the discovery and development of high-value drug classes through our end-to-end platform, enabling our biotechnology and pharmaceutical partners to deliver benefit to patients around the world.

arrow_forward arrow_back Targeted Protein Degradation
Axcelead has comprehensive capabilities in TPD drug discovery at the preclinical stages and a proven track record.
Learn More ›
RNA-Targeted
Small Molecules
Axcelead has comprehensive capabilities in integrated RNA-targeted small molecule drug discovery at the preclinical stages.
Learn More ›
Target Identification / Validation
Target Identification would have a significant impact in drug discovery research. Axcelead offers the platform to support the identification of novel drug target using human data driven transcriptomics and proteomics. Target validation of identified candidates is also performed in Axcelead using human samples and a variety of animal disease models.
Learn More ›
Hit Identification / Characterization
Axcelead will design a robust HTS strategy, starting from assay development through hit characterization, based on 700+ HTS experiences. Using carefully curated library sets from 1.5 million compounds inherited from a pharmaceutical company, we have achieved a success hit identification rate of 90+%.
Learn More ›
Lead Generation / Optimization
Axcelead has all must-have functions for efficient lead generation and optimization in one place, covering medicinal and analytical chemistries as well as in vitro and in vivo biology including DMPK and safety evaluation. Furthermore, Axcelead also uses proprietary in-silico systems with AI and high throughput synthesis technology to guide rational drug design and compound delivery.
Learn More ›
Candidate Selection
Candidate Selection is vital in drug discovery as in which, the optimized compounds are evaluated whether they are feasible for IND application filing and clinical studies. The candidate compound is selected and proposed based on the results of human effective dose prediction and safety assessment. Axcelead offers you one-stop and high-quality candidate selection by our accumulated experience.
Learn More ›
IND Enabling
Our proprietary process is designed to accelerate the development project time of your drug from candidate selection to IND filing, reduce R&D costs and achieve an IND in under 12 months. Smart-IND is a one-stop shop with Axcelead
Learn More ›
Advancing Oncology Research
We harness our wealth of expertise in target identification/validations, in vitro cell based assays, in vivo studies and translational research to achieve compounds with optimal profiles to perform well in the preclinical, clinical and real-world settings.
Learn More ›
Advancing Immunology Research
Our proprietary process focusses on obtaining the right immune and inflammatory reactions in cells from multiple species in our preclinical models, obtaining efficacy in our preclinical models and creating a novel MOA at our facility utilizing human tissue and blood samples.
Learn More ›
Advancing Cardiovascular / Metabolic Disease Research
Cardiovascular and metabolic diseases are complicated diseases involving various organs, and drug discovery requires deep expertise. At Axcelead, our team has abundant experience in drug discovery for heart failure, kidney diseases, obesity, MASH, etc.
Learn More ›
Advancing Neuroscience Research
When you partner with us, we will validate the scientific hypothesis of hitting a particular target based on the change of gene and protein expression using iPSC, patient-derived CSF, plasma and brain cells. Further, we will evaluate the potential of your compound using various measures of brain function and efficacy with behavioral tests specific to the development of neuroscience drugs.
Learn More ›
IND-Enabling Projects
Axcelead acquired multiple projects from Takeda through its spin-out in 2017 in multiple therapeutic areas including Oncology, Inflammation and Immunology, Metabolic Disorders and neuroscience. These exciting projects are available for co-creation of drug candidates with our customers.
Learn More ›
High Throughput Screening
Our integrated High Throughput Screening (HTS) platform, including a pharma-origin library of 1.5 million compounds, assay development capabilities, and a track record of over 700 projects, helps you rapidly identify your hit compounds.
Learn More ›
Chemistry
Axcelead leverages our expertise and technologies of rational drug design and synthetic chemistry to create the medicines of the future
Learn More ›
Oligonucleotide
Safety and delivery are the main challenges associated with discovering and developing complex oligonucleotides therapies. Axcelead offers a comprehensive platform that excels in repeating both in vivo and in vitro evaluations in the short term and proposing optimal solutions to help our partners overcome these challenges.
Learn More ›
Peptide
A Comprehensive One-Stop Solution for All Your Peptide Drug Discovery Challenges!

Axcelead has intelligent platform technologies to create peptide therapeutics with optimized profiles suitable for clinical development.
Learn More ›
Small Molecules
Small molecule drugs have been the dominant form in pharmaceuticals to date, and even as modalities diversify in the future, they are expected to continue to comprise the majority of newly approved drugs.
Learn More ›

Client Outcomes

We are your trusted partner.

At Axcelead, we have an aggressive mission to become the most trusted drug development solutions provider to leading biotechnology and pharmaceutical companies. Our wealth of expertise and knowledge stems from our robust client base, with over 100 facilities including pharmaceutical companies, venture companies and academia utilizing its services.

Our current partners in the US consist of cutting-edge companies developing new and proven drug candidates and modalities for oncology, immunology and neuroscience indications.

20
New Drug Applications
100
Successful IND Complete
90%
Hit Ratio of Screening

News

Our latest news and press releases.

We are ready to partner with you.

Go to Top